Statistical vs Clinical Significance: P-Values, Effect Sizes & MCID

In scientific research, a p-value is one of the most widely misunderstood metrics in statistics [1].

A p-value does NOT measure the size of a treatment effect, nor does it measure the probability that a drug is effective. It simply calculates the mathematical probability of observing the trial's data (or data more extreme) if the null hypothesis, the assumption that the drug has zero effect, were strictly true. By convention, p < 0.05 is deemed 'statistically significant', indicating that the observed data is unlikely to have occurred solely through random sampling variation [1].

While statistical significance is a mathematical calculation, clinical significance is a practical medical judgment [2].

Clinical significance asks: 'Does this treatment produce an improvement that is noticeably beneficial to the patient, justifies its financial cost, and outweighs its potential side effects?' If an experimental peptide accelerates wound healing by a statistically significant 4 hours over a 30-day recovery period (p = 0.02), the finding is statistically significant but of little or no clinical relevance (a hypothetical illustration).

To bridge statistics and medical practice, researchers establish the Minimal Clinically Important Difference (MCID) [3]. The MCID defines the smallest threshold of improvement that patients themselves perceive as beneficial.

Common clinical benchmarks include:

• Weight Loss: The FDA mandates that an anti-obesity drug achieve at least a 5% difference in mean weight loss over placebo to be considered clinically meaningful.
• Pain Scales: On a standard 0–100 mm Visual Analog Scale (VAS) for musculoskeletal pain, the accepted MCID is typically 15 to 20 mm. A peptide that achieves a statistically significant 4 mm reduction fails the MCID threshold.
• Diabetes: An HbA1c reduction of at least 0.3% to 0.5% is generally required to represent meaningful clinical glycemic improvement [3].

To properly evaluate research, scientists look past p-values to effect sizes and 95% Confidence Intervals (CIs) [4].

The 95% CI provides a range of plausible values for the true treatment effect in the population. If the lower boundary of the confidence interval falls below the established MCID, the trial cannot prove that the peptide delivers clinically meaningful benefit, even if p < 0.01 [4].

Comparing GLP-1 trials provides a classic demonstration of clinical significance [5]. Early diabetes therapies achieved statistically significant weight reductions of 1.5 kg (p < 0.001), but had minor clinical impact on obesity. In contrast, modern high-dose semaglutide (STEP-1, 14.9% mean weight loss) and tirzepatide (SURMOUNT-1, 20.9% mean weight loss) far exceed the 5% MCID, producing transformative improvements in sleep apnea, mobility, and cardiovascular events [5].